Tufts University School of Medicine, Boston, Massachusetts, USA.
School of Medicine, New York Medical College, Valhalla, New York, USA.
Pediatr Dermatol. 2024 Jul-Aug;41(4):733-735. doi: 10.1111/pde.15577. Epub 2024 Feb 27.
Guidelines are inconsistent regarding annual QuantiFERON® TB Gold (QFT) tests in children taking biologics for dermatological conditions, and there is limited research on seroconversion, especially in regions with high tuberculosis (TB) prevalence. A retrospective review of pediatric patients taking biologic treatment for psoriasis or hidradenitis suppurativa (HS) who had one baseline and at least one follow-up QFT test was conducted to assess for seroconversion during treatment. Thirty-two patients were included, with no instances of seroconversion. These findings suggest that routine annual TB rescreening for pediatric patients taking biologic therapy for dermatologic conditions may not be necessary without additional TB exposure risks or symptomatology.
指南对于接受生物制剂治疗皮肤病的儿童进行年度 QuantiFERON® TB Gold（QFT）检测并不一致，而且关于血清转换的研究有限，特别是在结核病（TB）高发地区。对接受生物制剂治疗银屑病或化脓性汗腺炎（HS）的儿科患者进行了一项回顾性研究，这些患者进行了一次基线和至少一次随访 QFT 检测，以评估治疗期间的血清转换情况。共纳入 32 例患者，均未发生血清转换。这些发现表明，在没有其他结核暴露风险或症状的情况下，对于接受生物制剂治疗皮肤病的儿科患者，常规进行年度结核再筛查可能没有必要。
